Skip to content

Prophylactic Ondansetron in Post-op Cardiac Surgery Patients to Prevent Post-operative Nausea and Vomiting

A Double-blinded, Randomized Control Trial of Prophylactic Ondansetron in a Post-operative Cardiac Surgery Population for Post-operative Nausea and Vomiting

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02966041
Enrollment
186
Registered
2016-11-17
Start date
2018-03-06
Completion date
2018-07-11
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Keywords

Postoperative Nausea and Vomiting, PONV, CSICU, post-cardiac surgery, cardiac intensive care unit

Brief summary

To evaluate the effectiveness of a prophylactic dose of ondansetron in decreasing the incidence of post-operative nausea and vomiting in cardiac surgery patients after cessation of post-operative sedation. In patients who have undergone open heart surgery, a single prophylactic dose of ondansetron 4 mg IV given at the time of discontinuing propofol sedation will result in a 50% reduction of the rate of post-operative nausea and vomiting in the first 24 post-operative hours compared to placebo.

Detailed description

Post-operative nausea and vomiting (PONV) is a significant source of morbidity for patients undergoing general anesthesia, and in particular, patients undergoing cardiac anesthesia. Despite its common occurrence, literature on PONV prophylaxis in the cardiac surgical population is limited relative to other surgical populations. A rational approach to preventing PONV would be to administer prophylaxis prior to extubation once post-operative sedation has ceased. This timing of administration would be more standardized across patients, as duration of surgery and time of extubation after surgery can vary considerably, rendering plasma levels of PONV prophylaxis agents highly variable across patients. At St. Paul's Hospital, PONV prophylaxis has not been a routine part of cardiac anesthesia care. Furthermore, there are no standardized guidelines, and practice varies between care providers. Following surgery, patients recover from anesthesia and are extubated in the cardiac surgery ICU (CSICU). They are usually sedated on a propofol infusion for one to four hours after surgery until they are ready for extubation. When PONV occurs, the first line drug for treatment is ondansetron 4 mg. The investigators therefore propose the use of a single, prophylactic dose of ondansetron (4 mg IV), given at the time of propofol cessation. A randomized, double blinded placebo controlled model will be utilized

Interventions

DRUGOndansetron

Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.

DRUGSaline

Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elective (outpatient) and urgent (inpatient) cardiac surgery procedures requiring cardiopulmonary bypass, including: * Coronary artery bypass grafting (CABG) * Valve surgery (ie. repair and/or replacement) * CABG and valve surgery

Exclusion criteria

* Undergoing 'off-pump' CABG (not involving the cardiopulmonary bypass machine) * With a contraindication to the study drug - including but not limited to congenital Long QT Syndrome, allergy to ondansetron, or a history of migraines * Unable to understand the consent process, either due to language limitations or cognitive limitations if a translator or substitute decision maker is not available * Receiving heart transplants, ventricular assist devices or on extra-corporeal membrane oxygenation (ECMO) * Intubated for more than 12 hours post-operatively * With a known history of PONV * Sedated with dexmedatomine instead of propofol

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of Post-operative Nausea and Vomiting (PONV)First 24 hours post-extubationMeasured by asking the patient hourly to assess their post operative nausea and vomiting using a 10-point verbal Likert rating scale.

Secondary

MeasureTime frameDescription
Time to first dose of rescue PONV medicationFirst 24 hours post-extubationTime of administration of first dose of rescue post-operative nausea and vomiting medication
Dose of any Rescue PONV medicationFirst 24 hours post-extubationDose of administered rescue post-operative nausea and vomiting medication after extubation.
Incidence of Post-operative nausea without vomitingFirst 24 hours post-extubationNurses both asked patients' for a nausea severity rating and recorded any vomiting hourly.
Incidence of Rescue PONV medication administrationFirst 24 hours post-extubationHow many participants received rescue post-operative nausea and vomiting medication post-extubation after surgery.
Severity Post-operative nausea without vomitingFirst 24 hours post-extubationSeverity of post-operative nausea without vomiting based on a 10-point likert scale, recorded hourly.
Incidence of ventricular arrhythmiasfirst 24 hours post-extubationAny sustained Ventricular Arrhythmias (i.e. lasting greater than 30 seconds)
Time to first report of nausea or first vomit post-operativelyFirst 24 hours post-extubationTime to first report of any nausea or vomiting after extubation post-operatively.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026